WoykaJTannaN.Consensus statement for non-oestrogen based treatment for menopausal symptoms. PRH2014;
20: 76–79.
2.
CummingGCurrieHMorrisE, et al.
The need to do better. Are we still letting our patients down and at what cost?PRH2015;
21: 56–62.
3.
BarbaMPizzutiLSergiD, et al.
Hot flushes in women with breast cancer: state of the art and future perspectives. Expert Rev Anticancer Ther2014;
14: 185–198.
4.
FisherWIJohnsonAKElkinsGR, et al.
Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA Cancer J Clin2013;
63: 167–192.
5.
L’EspéranceSFrenetteSDionneA, et al.
Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer2013;
21: 1461–1474.
6.
RadaGCapurroDPantojaT, et al.
Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev2010; (9): CD004923.
7.
LammerinkEAde BockGHSchröderCP, et al.
The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas2012;
73: 265–268.
8.
SiderasKLoprinziCL.Nonhormonal management of hot flashes for women on risk reduction therapy. J Natl Compr Canc Netw2010;
8: 1171–1179.
9.
National Institute for Clinical Excellence. Family breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer (CG164), June 2013, section 1.7.10–1.7.15.
10.
National Institute for Clinical Excellence Menopause Quality Standard,https//www.nice.org.uk/guidance/qs143 (9 February 2017, accessed 10 February 2017).
11.
National Institute for Clinical Excellence Menopause; clinical guideline-methods, evidence and recommendations (NG23) version 1.5, www.nice.org.uk/guidance/ng23 (12 November 2015, accessed 12 November2016).
12.
FreemanGSamuelMLinH, et al.
Duration of menopausal hot flushes and associated risk factors. Obstet Gynecol2011;
117: 1095–1104.
13.
AvisNGreendaleG.Duration of menopausal vasomotor symptoms over the menopause transition.JAMA Intern Med2015;
175: 539–531.
BleaseCRBishopFLKartchukTJ.Informed consent in trials: where is the placebo effect?BMJ2017;
356: j463.
16.
MarsdenJ.The menopause specialist and breast cancer survivorship.PRH2016;
22: 147–154.
17.
SturdeeD.Urogenital atrophy. PRH2014;
20: 73–75.
18.
SassariniJLumsdenMA.Non-hormonal management of vasomotor symptoms. Climacteric2013;
16: 31–36.
19.
CarrollDGKelleyKW.Use of antidepressants for management of hot flashes. Pharmacotherapy2009;
29: 1357–1374.
20.
VillasecaP.Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Climacteric2012;
15: 115–124.
21.
Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause2015; 22: 1155–1172.
NelsonHVescoKHaneyE, et al.
Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA2006;
295: 2057–2071.
24.
PandyaKJRaubertasRFFlynnPJ, et al.
Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flushes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med2000;
132: 788–793.
25.
RadaGCapurroDPantojaT, et al.
Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst Rev2010; (9): CD004923.
26.
OrleansRJLiLKimMJ, et al.
FDA approval of paroxetine for menopausal hot flushes. N Engl J Med2014;
370: 1777–1779.
27.
DesmaraisJELooperKJ.Managing menopausal symptoms and depression in tamoxifen users: implications of drug and medicinal interactions. Maturitas2010;
67: 296–308.
28.
Suvanto-LuukkonenEKoivunenRSundstromH, et al.
Citalopram and Fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomised 9 month, placebo controlled, double blind study. Menopause2005;
12: 18–26.
29.
KalayAEDemirBHaberalA, et al.
Efficacy of citalopram on climacteric symptoms.Menopause2007;
14: 223–229.
30.
LaCroixAZFreemanEWLarsonJ, et al.
Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas2012;
73: 361–368.
31.
EnsrudKEJoffeHGuthrieKA, et al.
Effect of escitalopram on insomnia symptoms and subjective sleep quality in healthy perimenopausal and postmenopausal women with hot flashes: a randomized controlled trial. Menopause2012;
19: 848–855.
32.
FreemanEWGuthrieKACaanB, et al.
Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA2011;
305: 267–274.
33.
RamaswamiRVillarrealMDPittaDM, et al.
Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat2015;
152: 231–237.
34.
LoprinziCLKuglerJWSloanJA, et al.
Venlafaxine in the management of hot flashes in survivors of breast cancer: a randomised, controlled trial. Lancet2000;
356: 2059–2063.
35.
EvamsMLPrittsEVittinghoffE, et al.
Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomised, controlled trial. Obstet Gynecol2005;
105: 161–166.
36.
SperoffLGassMConstantineG, et al.
Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomised controlled trail. Obstet Gynecol2008;
111: 77–87.
37.
HervikJBStubT.Adverse effects of non-hormonal pharmacological interventions in breast cancer survivors suffering from hot flashes: a systematic review and meta analysis. Breast Cancer Res Treat2016;
160: 223–236.
38.
JinYDestaZStearnsV, et al.
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst2005;
97: 30–39.
39.
LashTLCronin-FentonDAhernTP, et al.
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol2010;
49: 305–312.
40.
Huber-wechselbergerAENiedetzkyPAignerI, et al.
Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Wien Med Wochenschr2012;
162: 252–261.
41.
PandyaKJMorrowGRRoscoeJA, et al.
Gabapentin for hot flashes in 420 women with breast cancer: a double-blind placebo controlled trial. Lancet2005;
366: 818–2442.
42.
LoprinziCLQinRBalcuevaEP, et al.
Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol2010;
28: 641–647.
43.
LavigneJEHecklerCMathewsJL, et al.
A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat2012;
136: 479–486.
44.
PopATannaNPitkinJ.Breast cancer patient case study – prescribing of gabapentin for vasomotor symptom control and supporting patient compliance/concordance. Maturitas2009;
63: S53.
45.
YamaguchiNOkajimaYFujiiT, et al.
The efficacy of nonestrogenic therapy to hot flashes in cancer patients under hormone manipulation therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol2013;
139: 1701–1707.
46.
WiśniewskaIJochymekBLenart-lipińskaM, et al.
The pharmacological and hormonal therapy of hot flushes in breast cancer survivors. Breast Cancer2016;
23: 178–182.
47.
WoykaJ.Alternatives to hormone replacement therapy (HRT) (Sections 1 and 8). Post Reprod Health2016;
22: 67–69.
48.
ShahmohammadiARamezanpourNMahdavi SiukiM, et al.
The efficacy of herbal medicines on anxiety and depression in peri-and postmenopausal women: a systematic review and meta-analysis. Post Reprod Health2019;
25: 131–141.
49.
Maclaughlan DavidSSalzilloSBoweP, et al.
Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study. BMJ Open2013;
3: e003138.
GuirguisMAbdelmalakJJusinoE, et al.
Stellate ganglion block for the treatment of hot flashes in patients with breast cancer: a literature review. Ochsner J2015;
15: 162–169.
52.
MaoJJBowmanMAXieSX, et al.
Electroacupuncture versus gabapentin for hot flashes among breast cancer survivors: a randomized placebo-controlled trial. J Clin Oncol2015;
33: 3615–3620.
53.
PragueJKRobertsREComninosAN, et al.
Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action.Menopause Aug2018;
25: 862–869.
54.
AndersonRASkorupskaiteKSassariniJ, et al.
The neurokinin B pathway in the treatment of hot flushes.Climacteric2019;
22: 51–54.
